Four children with terminal brain cancer showed responses to a new cell therapy that few doctors have ever seen in this disease.
Quick Take
- One child had a complete response, with tumors no longer visible on brain scans.
- Three children were still alive years after treatment, far beyond the usual outlook.
- Nine of 11 patients showed neurologic improvement, including better walking, hearing, and taste.
- The results are striking, but the studies were early phase and built to test safety first.
A Rare Signal in a Deadly Disease
Researchers reported that a GD2-targeted chimeric antigen receptor T-cell therapy produced the first complete response ever recorded for diffuse intrinsic pontine glioma and related diffuse midline gliomas. In one case, tumors became undetectable on scans and stayed that way for more than 30 months, later updated to more than four years. The National Cancer Institute said the finding was unprecedented and justified real excitement, even as the trial remained small and early.
The treatment was given in phase 1 trials, which are designed mainly to test safety and feasibility, not prove cure. That matters because the sample sizes were tiny and there was no randomized control group. Even so, the results stood out: participants lived a median of 19.8 months after diagnosis in one study, far longer than the historical 11-month median often cited for this cancer.
What Changed for the Children
The strongest day-to-day changes were not just on scans. The National Cancer Institute reported that nine of 11 patients improved neurologically, and some regained abilities they had lost, including walking, hearing, and taste. Stanford researchers said some children who had been wheelchair-bound were walking within weeks. Tumors shrank by more than half in several patients, while others had smaller but still measurable reductions.
Those gains matter because diffuse intrinsic pontine glioma has long been treated as almost uniformly fatal. Standard care has offered little more than temporary control, and families have spent years hearing that nothing meaningful had worked. This trial did not erase that history, but it did break it open. For a disease that usually moves fast and leaves little room for hope, the long survivors changed the conversation.
Why Experts Are Cautious
Doctors are careful not to call this a cure for all children with the disease. Only one patient had a complete response, while most others had partial responses, stable disease, or shorter-lived benefit. Researchers also reported neuroinflammation that needed medical management, showing that the therapy can cause serious side effects even when it helps. The lead investigators said much work remains to refine and expand the approach.
Everyone's racing to engineer T cells for solid tumors. One of the most striking pediatric brain-cancer results this year came from T cells that weren't engineered at all.
Children's National just published a Phase 1 in Nature Medicine: multi-antigen T cells targeting WT1, PRAME…
— BioSignal (@BioSignal) July 7, 2026
That caution fits a wider pattern in pediatric cancer research. A dramatic response in one child can create headlines that race ahead of the data, especially when the disease is rare and deadly. This study does not settle the question of cure, but it does show that living immune cells can reach brain tumors and, in some cases, produce durable control. The next step is larger testing that can show who benefits most and how the treatment can be made safer.
Sources:
newscientist.com, pcrf-kids.org, ludwigcancerresearch.org, cancertodaymag.org, dipg.org, cancer.gov
